Rosalind Advisors
Latest statistics and disclosures from Rosalind Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DCTH, CYTK, FENC, VSTM, RZLT, and represent 37.07% of Rosalind Advisors's stock portfolio.
- Added to shares of these 10 stocks: EYPT (+$9.3M), GUTS (+$8.0M), ATYR (+$7.6M), QURE (+$7.3M), MDWD (+$6.2M), XFOR (+$5.3M), SVRA, CGON, CYBN, NSPR.
- Started 11 new stock positions in XFOR, QURE, GUTS, Verastem, Powershares Qqq Etf Put Opt 01/19 154.0 put, Rezolute, ATYR, Ishares Tr Index option, Scholar Rock Hldg Corp, EYPT. ATXS.
- Reduced shares in these 10 stocks: OCUL (-$9.6M), REPL (-$8.4M), URGN (-$7.4M), IDYA, PHVS, XERS, VRDN, TRVI, KALV, Inmune Bio.
- Sold out of its positions in CMPS, Crinetics Pharmaceuticals In, Inmune Bio, KALV, OVID, REPL, URGN, Urogen Pharma Ltd call, PHVS.
- Rosalind Advisors was a net buyer of stock by $29M.
- Rosalind Advisors has $293M in assets under management (AUM), dropping by 38.73%.
- Central Index Key (CIK): 0001622627
Tip: Access up to 7 years of quarterly data
Positions held by Rosalind Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rosalind Advisors
Rosalind Advisors holds 39 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Delcath Sys Com New (DCTH) | 11.3 | $33M | 3.3M | 10.00 |
|
|
| Cytokinetics Com New (CYTK) | 7.5 | $22M | 400k | 54.96 |
|
|
| Fennec Pharmaceuticals (FENC) | 6.6 | $19M | 2.1M | 9.36 |
|
|
| Verastem Com New (VSTM) | 5.8 | $17M | -5% | 1.9M | 8.83 |
|
| Rezolute Com New (RZLT) | 5.8 | $17M | +3% | 1.8M | 9.40 |
|
| Xeris Pharmaceuticals (XERS) | 5.0 | $15M | -16% | 1.8M | 8.14 |
|
| Savara (SVRA) | 4.9 | $14M | +50% | 4.0M | 3.57 |
|
| Mediwound Shs New (MDWD) | 4.6 | $14M | +84% | 749k | 18.02 |
|
| Miragen Therapeutics (VRDN) | 4.4 | $13M | -14% | 600k | 21.58 |
|
| Cg Oncology (CGON) | 4.1 | $12M | +55% | 300k | 40.28 |
|
| Verona Pharma Sponsored Ads (VRNA) | 3.6 | $11M | 100k | 106.71 |
|
|
| Ideaya Biosciences (IDYA) | 3.3 | $9.5M | -31% | 350k | 27.21 |
|
| Inspiremd (NSPR) | 3.2 | $9.4M | +70% | 3.9M | 2.41 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 3.2 | $9.3M | NEW | 650k | 14.24 |
|
| Mind Medicine Mindmed Com New (MNMD) | 3.0 | $8.8M | +78% | 750k | 11.79 |
|
| Cybin Com New (CYBN) | 3.0 | $8.8M | +84% | 1.5M | 5.89 |
|
| Fractyl Health (GUTS) | 2.7 | $8.0M | NEW | 5.0M | 1.59 |
|
| Atyr Pharma Com New (ATYR) | 2.6 | $7.6M | NEW | 1.0M | 7.28 |
|
| Uniqure Nv SHS (QURE) | 2.5 | $7.3M | NEW | 125k | 58.37 |
|
| X4 Pharmaceuticals Com New (XFOR) | 1.8 | $5.3M | NEW | 1.5M | 3.42 |
|
| Ocular Therapeutix (OCUL) | 1.6 | $4.7M | -67% | 400k | 11.69 |
|
| Atyr Pharma Put Put Option | 1.5 | $4.5M | +604% | 1.6M | 2.85 |
|
| Talphera Com New (TLPH) | 1.3 | $3.9M | +118% | 4.4M | 0.89 |
|
| Profound Med Corp Com New (PROF) | 1.2 | $3.4M | 692k | 4.89 |
|
|
| Myomo Com New (MYO) | 1.2 | $3.4M | +5% | 3.8M | 0.89 |
|
| Polypid (PYPD) | 1.0 | $3.1M | -5% | 919k | 3.33 |
|
| Invesco Qqq Tr Put Put Option | 0.5 | $1.6M | NEW | 250k | 6.23 |
|
| Biofrontera Com New (BFRI) | 0.4 | $1.1M | +16% | 1.1M | 0.98 |
|
| Astria Therapeutics (ATXS) | 0.4 | $1.1M | NEW | 1.5M | 0.72 |
|
| Spdr Series Trust Put Put Option | 0.3 | $951k | +286% | 2.1M | 0.45 |
|
| Trevi Therapeutics (TRVI) | 0.3 | $915k | -66% | 100k | 9.15 |
|
| Verastem Call Call Option | 0.3 | $898k | NEW | 647k | 1.39 |
|
| Kura Oncology (KURA) | 0.3 | $885k | 100k | 8.85 |
|
|
| Spdr S&p 500 Etf Tr Put Put Option | 0.2 | $718k | +20% | 300k | 2.39 |
|
| Rezolute Call Call Option | 0.2 | $546k | NEW | 263k | 2.08 |
|
| Ideaya Biosciences Call Call Option | 0.1 | $237k | +79% | 36k | 6.60 |
|
| Replimune Group Call Call Option | 0.1 | $183k | +120% | 511k | 0.36 |
|
| Ishares Tr Put Put Option | 0.0 | $20k | NEW | 200k | 0.10 |
|
| Scholar Rock Hldg Corp Put Put Option | 0.0 | $10k | NEW | 100k | 0.10 |
|
Past Filings by Rosalind Advisors
SEC 13F filings are viewable for Rosalind Advisors going back to 2023
- Rosalind Advisors 2025 Q3 filed Nov. 13, 2025
- Rosalind Advisors 2025 Q2 filed Aug. 14, 2025
- Rosalind Advisors 2025 Q1 filed May 14, 2025
- Rosalind Advisors 2024 Q4 restated filed Feb. 14, 2025
- Rosalind Advisors 2024 Q3 filed Oct. 30, 2024
- Rosalind Advisors 2024 Q2 filed July 12, 2024
- Rosalind Advisors 2024 Q1 filed April 25, 2024
- Rosalind Advisors 2023 Q4 filed Feb. 14, 2024